60th Annual Meeting of the Japanese Society of Neurology

Session information

Print

Hot Topics

[HT-10] Motor neuron diseases in the era after translational research

Sat. May 25, 2019 8:00 AM - 10:00 AM Room 4 (Osaka International Convention Center 10F Conference Room 1001-1002)

Chair:Makoto Urushitani(Department of Neurology, Shiga University of Medical Science, Japan), Kentaro Sahashi(Department of Neurology, Nagoya University Graduate School of Medicine, Japan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.

[HT-10-1] Molecular mechanisms of neuromuscular degeneration in spinal and bulbar muscular atrophy

Madoka Iida (Nagoya Univ. Graduate School of Medicine, Department of Neurology, Japan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.

[HT-10-2] Pathogenesis and Therapy of Spinal Muscular Atrophy

Yuh-Jyh Jong1,2,3 (1.Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Taiwan, 2.Departments of Pediatrics and Laboratory Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taiwan, 3.College of Biological Science and Technology, National Chiao Tung University, Taiwan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.

[HT-10-3] Oligonucleotide drug for treatment of ALS

Takanori Yokota (Dept.of Neurology and Neurological Science,Tokyo Medical and Dental Univ., Japan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.

[HT-10-4] Investigation and Drug Development of ALS using iPSCs technology and Clinical Trial

Hideyuki Okano (Keio University School of Medicine, Japan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.